Retatrutide — compound monograph
Triple GIP, GLP-1 and glucagon receptor agonist (acylated). Phase 3. The Institute assesses 4 outcomes for this compound and grades the strongest at moderate certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Retatrutide
- Compound class
- Triple GIP, GLP-1 and glucagon receptor agonist (acylated)
- Assessment series
- Incretin receptor agonists
- Synonyms and codes
- LY3437943 · retatrutide (INN) · triple agonist LY3437943
- Route as evaluated
- Subcutaneous once weekly
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Average mass
- 4731.3
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
The complete residue-by-residue sequence has been published in the medicinal-chemistry literature but the Institute reproduces only the structural description here pending confirmation of a single authoritative sequence record. Suppliers offering "retatrutide" for research use frequently cannot document which sequence variant they have synthesised, which is a material analytical concern.
§1.4Assessment status
The Institute assesses Retatrutide across 4 indications and grades the strongest of them at moderate certainty. In confirmatory clinical development; no marketing authorisation.
Table 1. Assessed outcomes for Retatrutide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −24.2 % body weight at 48 weeks with 12 mg in the phase 2 trial versus −2.1 % with placebo | Moderate | 3 |
| Type 2 diabetes mellitus | −2.02 % HbA1c at 36 weeks with 12 mg versus −0.01 % with placebo; weight −16.9 % | Moderate | 2 |
| Metabolic dysfunction-associated steatohepatitis | Liver-fat reduction exceeding 80 % relative at higher doses in a phase 2 imaging substudy | Low | 1 |
| Obstructive sleep apnoea with obesity | Not yet reported | Not rated | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.